CompletedNCT03508700
Long-Term Safety of TNX-102 SL for People With PTSD
About this title
Read the official source — NCT03508700Medication studyAges 18–75United States
Understand this study
Who was this study for?
This study was for people with PTSD. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 15 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: April 19, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 93
- Sponsor
- Tonix Pharmaceuticals, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT03508700
- Official title
Show the full official title
A 40-week Open-Label Extension Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Little Rock · Beverly Hills · Oceanside
13 more locations
- Orange
- Temecula
- Colorado Springs
- Norwich
- Tampa
- Atlanta
- New Bedford
- Las Vegas
- Cedarhurst
- New York
- Canton
- Cincinnati
- Oklahoma City
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Tonix Pharmaceuticals, Inc.
Did this study involve medication?
Yes. The study involved medication, including TNX-102 SL 5.6 mg.
Who was this study for?
This study was for people with PTSD. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
